Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from EKF Diagnostics Holdings ( (GB:EKF) ) is now available.
EKF Diagnostics has executed a share buyback, purchasing 15,000 ordinary shares at a weighted average price of 23.43 pence, with all acquired shares to be held in treasury rather than cancelled. The transaction leaves the company with an issued share capital of 431,963,112 ordinary shares, of which 1,010,000 are in treasury, resulting in 430,953,112 shares carrying voting rights for regulatory disclosure purposes.
The modest repurchase, with no shares sold by major shareholder Harwood Capital Management in this tranche, marginally increases the proportionate holdings of existing investors and may be read as a signal of management confidence in EKF’s valuation. The updated voting rights figure provides clarity for shareholders monitoring their disclosure thresholds under the FCA’s transparency rules, supporting orderly trading and compliance in the AIM-listed stock.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £26.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
Spark’s Take on EKF Stock
According to Spark, TipRanks’ AI Analyst, EKF is a Neutral.
The score is driven by solid financial resilience (low leverage and generally healthy cash generation) and a constructive earnings outlook (margin improvement, capacity expansion, new contracts, and buyback). These positives are tempered by weak technicals (price below major moving averages and negative MACD) and only mid-range valuation support (P/E ~15.6, no dividend yield provided).
To see Spark’s full report on EKF stock, click here.
More about EKF Diagnostics Holdings
EKF Diagnostics Holdings is an AIM-listed global diagnostics company focused on point-of-care analysers in hematology and diabetes, as well as life sciences services that manufacture specialist enzymes and custom products for diagnostic, food and industrial uses. Headquartered in Penarth near Cardiff, the group operates five manufacturing sites across the U.S. and Germany and sells into more than 120 countries worldwide.
Average Trading Volume: 360,235
Technical Sentiment Signal: Strong Sell
Current Market Cap: £100.8M
Learn more about EKF stock on TipRanks’ Stock Analysis page.